Indivior (NASDAQ:INDV – Get Free Report) and Siga Technologies (NASDAQ:SIGA – Get Free Report) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their institutional ownership, earnings, profitability, analyst recommendations, dividends, valuation and risk.
Institutional & Insider Ownership
60.3% of Indivior shares are owned by institutional investors. Comparatively, 55.4% of Siga Technologies shares are owned by institutional investors. 0.7% of Indivior shares are owned by company insiders. Comparatively, 2.7% of Siga Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Analyst Recommendations
This is a summary of recent ratings for Indivior and Siga Technologies, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Indivior | 0 | 1 | 6 | 0 | 2.86 |
| Siga Technologies | 1 | 0 | 0 | 0 | 1.00 |
Profitability
This table compares Indivior and Siga Technologies’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Indivior | 26.65% | -283.11% | 36.85% |
| Siga Technologies | -5.19% | -1.55% | -1.32% |
Risk & Volatility
Indivior has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Siga Technologies has a beta of 0.97, suggesting that its share price is 3% less volatile than the S&P 500.
Valuation & Earnings
This table compares Indivior and Siga Technologies”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Indivior | $1.24 billion | 3.32 | $210.00 million | $2.79 | 12.50 |
| Siga Technologies | $94.57 million | 2.39 | $23.28 million | ($0.05) | -62.80 |
Indivior has higher revenue and earnings than Siga Technologies. Siga Technologies is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.
Summary
Indivior beats Siga Technologies on 11 of the 14 factors compared between the two stocks.
About Indivior
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose. Its core marketed products include SUBLOCADE and SUBUTEX PRO buprenorphine extended-release monthly injections; SUBOXONE, a buprenorphine and naloxone sublingual film; SUBOXONE, a buprenorphine and naloxone sublingual tablet; and SUBUTEX, a buprenorphine sublingual tablet for the treatment of opioid use disorder. The company also offers OPVEE nasal spray for opioid overdose reversal; and PERSERIS extended-release injectable suspension for the treatment of schizophrenia in adults. In addition, it is developing INDV-2000, a selective orexin-1 receptor antagonist that completed phase 1 clinical trial for the treatment of opioid use disorder (OUD); INDV-1000, a selective GABAb positive allosteric modulator, which is in pre-clinical development phase for the treatment of alcohol use disorder in collaboration with ADDEX therapeutics; INDV-6001, a buprenorphine-based long-acting injectable for the treatment of OUD in collaboration with Alar Pharmaceuticals Inc.; and CT-102, a digital therapeutic for the treatment of OUD in collaboration with Click Therapeutics. Further, the company is developing INDV-5004, a drinabant injection to treat acute cannabinoid overdose. It has a strategic partnership with Aelis Farma to develop AEF0117, a synthetic CB1 specific signaling inhibitor that is in phase 2B clinical trial for the treatment of cannabis use disorder. The company was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.
About Siga Technologies
SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.
Receive News & Ratings for Indivior Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Indivior and related companies with MarketBeat.com's FREE daily email newsletter.
